Health Care • Medical/Dental Instruments
$14.45 ▲ +0.13
(+0.91%)
MKT CAP: $287.8M • VOL: 74.9K
52W L $7 52W H $15
INFU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $143.4M | $134.9M | $125.8M |
| YoY Revenue Growth % | +6.4% | +7.2% | — |
| Gross Profit | $80.3M | $70.4M | — |
| Gross Margin % | 56.0% | 52.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $11.9M | $6.9M | $4.1M |
| Operating Margin % | 8.3% | 5.1% | 3.2% |
| Net Income (GAAP) | $6.6M | $2.3M | $872.0K |
| EBITDA (Normalized) | $12.4M | $7.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $24.4M | $20.5M | $11.2M |
| Capital Expenditures (CapEx) | $560.0K | $1.1M | — |
| Free Cash Flow (FCF) | $23.8M | $19.4M | $11.2M |
| FCF Margin % | 16.6% | 14.4% | 8.9% |
| Return on Invested Capital (ROIC %) | 12.8% | 6.7% | — |
| Cash & Short-Term Equivalents | $3.2M | $527.0K | — |
| Total Debt (Short + Long Term) | $19.6M | $23.9M | — |
| Total Stockholders' Equity | $57.3M | $57.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INFU.